Next-Generation Cancer Therapeutics Market Revenue to Attain USD 163.2 Bn by 2033

10 Jul 2025

Share :

Table of Content

1. Next-Generation Cancer Therapeutics Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Insights: 4. Regional Insights 5. Next-Generation Cancer Therapeutics Market Coverage 6. Next-Generation Cancer Therapeutics Market Key Players

Next-Generation Cancer Therapeutics Market Revenue and Trends 2025 to 2033

The global next-generation cancer therapeutics market revenue is estimated to be valued at USD 92.54 billion in 2025 and is predicted to attain around USD 163.2 billion by 2033, at a CAGR of 7.35%. The market growth is attributed to the increasing global cancer burden and rising demand for more precise, effective, and personalized treatment options with fewer side effects.

Market Overview

The next-generation cancer therapeutics market is experiencing rapid growth, driven by the increasing incidence of cancer worldwide, which necessitates more effective and personalized therapies for a wide range of cancers. Advancements in biotechnology, including gene editing (CRISPR), mRNA platforms, and CAR T cell therapy, are changing the way how cancer is treated by providing targeted solutions with significantly fewer side effects. The growing interest in precision medicine is likely to drive market growth.

Advances in genomics lead to early diagnosis of cancer, enabling timely intervention to minimize future risks. Governments around the world are funding cancer research and development, creating immense opportunities in the market. Moreover, the rising demand for personalized combination therapies opens up new growth avenues.

Segment Insights:

• By therapy type, the targeted therapy segment continues to be a dominant force in the market due to the rising development of precise and effective targeted therapies. Due to the proven effectiveness in treating a spectrum of cancers and reduced side effects, targeted therapies have become one of the standard treatments in the field of oncology.
• By cancer type, the lung cancer segment dominated the market with the largest share in 2024. This is due to the high burden of lung cancer around the world. As it is a major cause of cancer-related deaths worldwide, there is an urgent need for effective, novel treatments to reduce the mortality rate associated with lung cancer.
• By modality, the monotherapy segment dominated the market in 2024. Monotherapies are preferred for their reduced side effects and targeted approach. Better patient compliance and proven clinical efficacy contribute to their increased adoption.
• By route of administration, the intravenous (IV) segment led the market in 2024 due to its precision dosing and systemic rapid delivery. IV therapies are gaining traction as the standard of care in oncology practice.
• By mechanism of action, immune activation (checkpoint inhibition) remains the dominant segment in the market. This is mainly due to the rising demand for novel immunotherapies. Immune activation through checkpoint inhibition blocks immune checkpoints, preventing them from attacking healthy cells and increasing the survival rates of cancer patients.
• By end-user, the specialty cancer hospitals segment dominated the market in 2024. This is mainly due to the increased cancer patient burden in these settings due to their advanced infrastructures and the availability of skilled expertise.

Regional Insights

North America dominated the next-generation cancer therapeutics market in 2024 due to the increased cancer R&D activities, high adoption rates of innovative therapies, and favorable regulatory environment. The rising approvals for novel drugs and a strong emphasis on a patient-centric care approach support market growth.

Asia Pacific is expected to grow at the highest CAGR in the upcoming period. This is mainly due to the rising burden of cancer. Governments of various Asian countries, including China and India, are focusing on reducing the cancer burden and mortality rate associated with it. Thus, they are investing heavily in R&D to develop novel therapeutics, contributing to regional market growth.

Next-Generation Cancer Therapeutics Market Coverage

Recent Development

• In June 2024, AstraZeneca and its partner Daiichi Sankyo received approval from U.S. regulators for their precision drug Datroway to treat lung cancer, marking the first approval of the therapy in this indication and expanding access for patients.

Next-Generation Cancer Therapeutics Market Key Players

• Roche Holding AG
• Bristol Myers Squibb
• Merck & Co., Inc.
• Pfizer Inc.
• Novartis AG
• AstraZeneca plc
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Seagen Inc. (Pfizer)
• Amgen Inc.
• Genentech, Inc.
• Moderna, Inc.
• BioNTech SE
• Bluebird Bio, Inc.
• BeiGene, Ltd.
• Innovent Biologics
• Immatics Biotechnologies
• Adaptimmune Therapeutics
• Fate Therapeutics
• Legend Biotech Corporation 

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6370

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344